Compound A Suppressing Retinal Vascular Permeability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for eye diseases such as age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion do not effectively inhibit the functions of vascular endothelial growth factor (VEGF), which contributes to increased retinal vascular permeability and neovascularization.
Innovation Solution
The use of Compound A, a specific chemical compound, or its pharmaceutically acceptable salt, which suppresses the increase of retinal vascular permeability induced by VEGF, thereby providing therapeutic or preventive benefits for various eye diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for eye diseases, then treatment is provided, but VEGF functions are not effectively inhibited, resulting in increased retinal vascular permeability and neovascularization
Solution Approach 1:
The patent introduces a novel compound A with a specific chemical structure that represents a parameter change in the therapeutic agent class. This compound achieves effective VEGF inhibition through its unique molecular configuration, resolving the contradiction by providing a new chemical parameter (compound structure) that delivers reliable VEGF inhibition while controlling retinal vascular permeability.
2Reliability
If VEGF functions are inhibited to suppress retinal vascular permeability and neovascularization, then treatment effectiveness improves, but new therapeutic agents are required
Solution Approach 1:
The patent segments the therapeutic approach by introducing compound A as a distinct chemical entity with specific structural features (3-[(3S,4R)-3-Methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile). This segmentation creates a new, manufacturable therapeutic agent that achieves VEGF inhibition, resolving the contradiction between treatment effectiveness and agent availability.
Data Source
AI summary
3-[(3S,4R)-3-Methyl-6-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile suppresses an increase of the retinal vascular permeability induced by VEGF, it can be used as an active ingredient of a therapeutic or preventive agent for various eye diseases involving VEGF, such as age-related macular degeneration, diabetic retinopathy, macular edema, neovascular maculopathy, retinal vein occlusion and neovascular glaucoma.